



FIND THE BEST PERSONALIZED CANCER THERAPY – TODAY

ONCOMPASS™ IS A MOLECULAR DIAGNOSTICS BASED THERAPEUTIC INFORMATION SERVICE FOR PRECISION ONCOLOGY

Winner of DIGITALEUROPE's Future Unicorn Award:

The most promising European technology company with a future value of more than \$ 1 billion.



Winner of the GET IN THE RING


Global Start Up competition, Health category 2020/21



TEST



ANALYZE



DECIDE

Barbara Vodicska, PhD – Senior R&D Scientist

István Peták, MD PhD - Founder, CEO

Semmelweis University, Dept of Pharmacology and Pharmacotherapy
University of Illinois at Chicago, Dept of Biopharmaceutical Sciences

RealTime Oncology Treatment Calculator™
CE-marked medical device

- 1.200+ drugs
- 2.300+ genes
- 36.000+ mutations
- 1.400+ clinical trials
- 14.000+ evidence
- 23.000+ rules

WORKFLOW OF PRECISION ONCOLOGY



Curated databases to link alterations to guidelines, registration, „one by one”

Standardized and reproducible algorithm to prioritize drivers, targets, therapies based on molecular evidence

Decision based on the molecular evidence and clinical factors (side effects, costs, patient preference etc.)

Why do we need digital drug-assignment?

Cancers harbor multiple drivers (3-4), and the efficacy of most drugs is influenced by multiple predictive parameters.

Single biomarker paradigm →
Multi-parametric approach




**Partnering for Lot 4
with an ESCAT- or other single biomarker-based
reporting solution**

Multiparameter-based digital drug-assignment for treatment planning in precision oncology

RealTime Oncology Treatment Calculator



Tumor type, molecular alterations (SNV, CNV, TMB, MSI, IHC, FISH)
Any NGS Panels e.g. FMI reports



Personalized, prioritized list of compounds

- ✓ Explainable
- ✓ Evidence-based
- ✓ Reproducible


Evidence-based network of associations and algorithms




AEL
Aggregated Evidence Level represents the number, scientific impact and clinical relevance of evidence relations connecting tumor types, molecular alterations, targets and compounds.

The SHIVA01 clinical trial

Original – single biomarker approach by picking




RealTime Oncology TC – multiparametric approach



Dirner et al., J Clin Oncol 38: 2020 (suppl; abstr 3642) and accepted manuscript

Reanalysis by ESCAT categories – single biomarker approach



Moreira, A. et al European Journal of Cancer, Volume 121, 202 – 209. 2019

Patients with high AEL treatment had longer PFS

**RealTime Oncology Treatment Calculator
a reporting method that correlates with outcome**

Utility of RealTime Oncology today

- **Decision between treatment options at the same evidence level** (e.g. with same ESCAT category)
- **Decision between multiple on-label molecularly targeted agents registered in the same indication** (e.g different EGFR inhibitors in NSCLC, anti-Her2 agents in BC, PARP inhibitors in OC&BC)
- **Decision between off-label molecularly targeted agents at the same evidence level** (salvage therapy, pediatric cancers in combination with chemotherapy)

Utility is increasing with new approvals,
and with the increasing complexity of input data.



Contact us for Lot4:

Barbara Vodicska, PhD – Senior Scientist
barbara.vodicska@oncompassmedicine.com

István Peták, MD PhD - Founder, CEO
istvan.petak@oncompassmedicine.com

www.oncompassmedicine.com
www.realtimeoncology.com